| Serial Number | 88692164 |
| Word Mark | NOVOCOL PHARMA |
| Filing Date | Thursday, November 14, 2019 |
| Status | 688 - NOTICE OF ALLOWANCE - ISSUED |
| Status Date | Tuesday, April 16, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, February 20, 2024 |
| Goods and Services | (Based on 44(e)) Contract manufacturing of clinical batches of pharmaceuticals; (Based on Intent to Use) consulting services relating to pharmaceutical manufacturing and batch biological treatment batches; none of the foregoing for the treatment of cancer or oncological diseases and disorders |
| Description of Mark | The mark consists of a design element in the top-left corner of overlapping arced lines with the bottom line in red and the top line in blue, with the word "NOVOCOL" in blue lower-case design and underneath to the right the word "PHARMA" in smaller red lower-case design. |
| Goods and Services | (Based on 44(e)) Pharmaceutical products, namely, acne medication, allergy medication, antacids, anthelmintics, antiarrhythmics, antibiotic creams and ointments, antibiotics, anticoagulants, anticonvulsants, antidepressants, antiemetics, antiflatulants, antihistamines, antihypertensives anti-infectives, anti-inflammatories, antiparasites, antivirals, burn relief medication, calcium channel blockers, central nervous system depressants, central nervous system stimulants, cough treatment medication, diarrhea medication, fungal medications, gastro-intestinal pharmaceutical preparations, glaucoma agents, hydrocortisone, hypnotic agents, sedatives, pain relief medication, and topical and injectable pharmaceutical preparations for dental, endodontic and periodontal disorders; anti-epileptic pharmaceutical preparations; bismuth preparations for pharmaceutical use; bromine for pharmaceutical purposes; cardiovascular pharmaceutical preparations; frostbite salve for pharmaceutical purposes; guaiacol for pharmaceutical purposes; intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; injectable pharmaceutical contraceptives; pharmaceutical anti-allergic preparations and substances; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely, infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely, bulimia nervosa, anorexia, and hypothyroidism; pharmaceutical preparations for the treatment of migraine; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, multiple sclerosis; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of respiratory diseases, disorders and infections; pharmaceutical preparations for the treatment of skin irritations, namely, bee stings, sunburn, rashes, sores, corns, calluses, and acne; pharmaceutical preparations for the treatment of smoking cessation; pharmaceutical preparations for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases; pharmaceutical preparations for the treatment of the central nervous system, namely, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease; pharmaceutical preparations for the treatment of the diseases, disorders and infections of the central nervous system, namely, brain, movement, ocular motility and spinal cord diseases; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of the respiratory system; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating dandruff; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in discouraging the smoking habit; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for wounds; pharmaceutical preparations for treatment of dry skin caused by pregnancy; pharmaceutical preparations for hydrating the skin during pregnancy; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for treating respiratory diseases; pharmaceutical solutions used in dialysis; radioactive pharmaceutical preparations for in vivo diagnostic or therapeutic use; sunburn preparations for pharmaceutical purposes; synthetic peptides for the treatment of all of the foregoing diseases and conditions; disinfection systems, namely, all-purpose disinfectants; none of the foregoing for the treatment of cancer or oncological diseases and disorders |
| Indication of Colors claimed | The color(s) blue and red is/are claimed as a feature of the mark. |
| Goods and Services | (Based on 44(e)) Business consulting services relating to pharmaceutical manufacturing, clinical evaluation and testing, regulatory registration, stability studies, method development, formal stability, registration batches and commercial production; none of the foregoing for the treatment of cancer or oncological diseases and disorders |
| Goods and Services | (Based on 44(e)) Consulting services to assist companies with obtaining regulatory compliance and licenses for pharmaceuticals and medical devices; (Based on Intent to Use) consulting services relating to pharmaceuticals in the field of regulatory compliance, namely, regulatory registration; none of the foregoing for the treatment of cancer or oncological diseases and disorders |
| NOT AVAILABLE | "PHARMA" |
| Goods and Services | (Based on 44(e)) Drug delivery systems, consisting of needles, syringes, nasal spray bottles, injection devices, oral and nasal inhalation devices, patch pumps, and anesthetic delivery apparatus for medical purposes, but not for use in the fields of diabetes and obesity; none of the foregoing for the treatment of cancer or oncological diseases and disorders |
| Goods and Services | (Based on 44(e)) Pharmaceutical drug development services, namely, the formulation of new dosage forms and the reformulation of existing drug products; (Based on Intent to Use) consulting services relating to clinical testing, inspection, or research of pharmaceuticals; consulting services relating to conducting pharmaceutical stability studies and formal stability studies; consulting services relating to the development of chemical production methods; consulting services relating to registration batch research and commercial pharmaceutical products development; none of the foregoing for the treatment of cancer or oncological diseases and disorders |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 20, 2019 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 20, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 20, 2019 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 035 - Advertising; business management; business administration; office functions. |
| US Class Codes | 100, 101, 102 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 20, 2019 |
| Primary Code | 035 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 20, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, November 20, 2019 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Septodont Holding SAS |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Saint-Maur-des fosses Cedex9410 FR |
| Party Name | Septodont Holding SAS |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Saint-Maur-des fosses Cedex9410 FR |
| Event Date | Event Description |
| Monday, November 18, 2019 | NEW APPLICATION ENTERED |
| Wednesday, November 20, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, November 21, 2019 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Wednesday, February 19, 2020 | ASSIGNED TO EXAMINER |
| Thursday, February 20, 2020 | NON-FINAL ACTION WRITTEN |
| Thursday, February 20, 2020 | NON-FINAL ACTION E-MAILED |
| Thursday, February 20, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, March 13, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, March 13, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, March 13, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, March 18, 2020 | SUSPENSION LETTER WRITTEN |
| Wednesday, March 18, 2020 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, March 18, 2020 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Friday, September 18, 2020 | SUSPENSION INQUIRY WRITTEN |
| Friday, September 18, 2020 | INQUIRY TO SUSPENSION E-MAILED |
| Friday, September 18, 2020 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Monday, September 21, 2020 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Wednesday, December 16, 2020 | ASSIGNED TO LIE |
| Monday, December 28, 2020 | ASSIGNED TO LIE |
| Tuesday, December 29, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Tuesday, December 29, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, December 30, 2020 | SUSPENSION LETTER WRITTEN |
| Wednesday, December 30, 2020 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, December 30, 2020 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Thursday, July 1, 2021 | SUSPENSION INQUIRY WRITTEN |
| Monday, January 3, 2022 | ASSIGNED TO LIE |
| Thursday, July 1, 2021 | INQUIRY TO SUSPENSION E-MAILED |
| Thursday, July 1, 2021 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Tuesday, December 28, 2021 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Monday, January 10, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, January 10, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, January 10, 2022 | SUSPENSION LETTER WRITTEN |
| Monday, January 10, 2022 | LETTER OF SUSPENSION E-MAILED |
| Monday, January 10, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Tuesday, March 1, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Tuesday, March 1, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, March 1, 2022 | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Tuesday, March 1, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, March 9, 2022 | ASSIGNED TO EXAMINER |
| Monday, July 18, 2022 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Monday, August 8, 2022 | SUSPENSION INQUIRY WRITTEN |
| Monday, August 8, 2022 | INQUIRY TO SUSPENSION E-MAILED |
| Monday, August 8, 2022 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Wednesday, February 1, 2023 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Wednesday, February 8, 2023 | ASSIGNED TO LIE |
| Wednesday, February 8, 2023 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, February 8, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, February 8, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, February 8, 2023 | SUSPENSION LETTER WRITTEN |
| Wednesday, February 8, 2023 | LETTER OF SUSPENSION E-MAILED |
| Wednesday, February 8, 2023 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
| Saturday, September 2, 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Monday, September 18, 2023 | ASSIGNED TO EXAMINER |
| Wednesday, September 27, 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
| Monday, October 2, 2023 | SUSPENSION INQUIRY WRITTEN |
| Monday, October 2, 2023 | INQUIRY TO SUSPENSION E-MAILED |
| Monday, October 2, 2023 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
| Thursday, December 21, 2023 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
| Saturday, December 23, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Saturday, December 23, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, January 16, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, January 16, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Tuesday, January 16, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Tuesday, January 16, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, January 17, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, February 1, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Wednesday, January 31, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, February 1, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Thursday, February 8, 2024 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Tuesday, February 20, 2024 | PUBLISHED FOR OPPOSITION |
| Monday, March 4, 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Monday, March 11, 2024 | ASSIGNED TO PETITION STAFF |
| Tuesday, March 12, 2024 | CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED |
| Wednesday, October 16, 2024 | TEAS STATEMENT OF USE RECEIVED |
| Wednesday, October 16, 2024 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, April 16, 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |